Drug profile · INN
lanadelumab-flyo
TAKHZYRO
lanadelumab-flyo (TAKHZYRO) is a plasma kallikrein inhibitor. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — lanadelumab-flyo
- US status
- approved
- Class
- —
- Route
- SUBCUTANEOUS
- Patents
- 0
- Programs
- 6
- Data quality
- 0.84
Quick answer
lanadelumab-flyo (TAKHZYRO) is a plasma kallikrein inhibitor. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
Plasma kallikrein inhibitor
Primary target: Plasma kallikrein
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is lanadelumab-flyo?
lanadelumab-flyo (TAKHZYRO) is a plasma kallikrein inhibitor. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for lanadelumab-flyo?
TAKHZYRO is a marketed brand name for lanadelumab-flyo. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of lanadelumab-flyo?
lanadelumab-flyo has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.